glatiramer acetate

Key facts

INN

glatiramer acetate

Brand

GLATOPA

Route

SUBCUTANEOUS

Formulation

INJECTABLE

Originator

TEVA PHARMACEUTICAL INDUSTRIES LTD

Related patents

patent

US 9763993

Process for manufacturing glatiramer acetate product

Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9702007

Genetic markers predictive of response to glatiramer acetate

Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9687522

Methods of treating a subject afflicted with an autoimmune disease using predict

Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9625473

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer

Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9499868

Determination of single nucleotide polymorphisms useful to predict response for

Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9155775

Process for manufacturing glatiramer acetate product

Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 9063153

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer

Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

Frequently asked questions

What is glatiramer acetate?

glatiramer acetate (GLATOPA), is a pharmaceutical active ingredient, associated with TEVA PHARMACEUTICAL INDUSTRIES LTD, with approved status in the US.

What is the brand name for glatiramer acetate?

GLATOPA is a marketed brand name for glatiramer acetate. Check FDA Drugs@FDA for the current US label holder.